Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2015 Earnings Results

Alnylam Pharmaceuticals Misses on EPS, Stock Down 6.15%

Alnylam Pharmaceuticals reported a loss that was slightly worse than expected, which contributed to a 6.15% decline in the stock price. The lack of revenue figures and guidance adds uncertainty for investors. Overall, the results indicate challenges ahead for the company.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.85	N/A	-14.86%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Unknown

No transcript is on record for the earnings call, so the analysis is based solely on numerical results.

Alnylam Pharmaceuticals Misses on EPS, Stock Down 6.15%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Misses on EPS, Stock Down 6.15%

Key numbers

Management commentary